Drugs / VIR-5818
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05356741 | Apr 2022 → Aug 2027 expected | carcinoma | Vir Biotechnology, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-01-08 | Vir Biotechnology, Inc. | Results Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC vir.bio ↗
Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-01-08 | Vir Biotechnology, Inc. | Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC vir.bio ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIR-5818 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05356741 ↗ |
| Known as | AMX-818 | “This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation and dose-expansion study is designed to evaluate the safety, pharmacokinetics, and preliminary activity...” NCT05356741 ↗ |
| Route | Intravenous | “Administered as IV infusion” NCT05356741 ↗ |